The influence of valsartan on MAU of patients with diabetic nephropathy(DN) at early stage
10.3760/cma.j.issn.1008-6706.2011.12.011
- VernacularTitle:缬沙坦治疗早期糖尿病肾病82例临床观察
- Author:
Rongjun LIANG
;
Yeming LU
;
Xiaohui LI
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathies;
Albuminuria;
Valsartan
- From:
Chinese Journal of Primary Medicine and Pharmacy
2011;18(12):1606-1607
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore influence of valsartan on MAU of patients with DN at early stage.Methods 163 patients with DN at early stage were randomly divided into experimental group and control group.Two groups were given routine therapy, and experimental group were added the therapy of valsartan.Period of treatment was 24 weeks, and compared the UAER, Cr, BUN of two groups.Results After treatment of 24 weeks, UAER, Cr, BUN of experimental groups was (142.4 ± 15.6) μg/min, ( 68.7 ±9.4) μmol/L, (3.5 ± 1.2 ) mmol/L, compared with (195.8±23.7)(μg/min,(93.8 ± 13.6) μmol/L, (6.3 ±1.5) mmol/L before treatment, had significant difference (t = 13.675,11.287,2.469,all P<0.05).Compared with( 199.6 ±24.7)μg/min,(87.7 ±11.3)μmol/L、(6.2 ± 1.3)mmol/L of control group after treatment, declined more significantly (t = 13.246,10.312,2.518,all P<0.05).There was no serious complications occurred in two groups.Conclusion Valsartan used in patients with DN at early stage,can significantly improve the function of kidney and enhance clinical effect,decline the side reaction.